 RESEARCH TRIANGLE PARK, N.C., June 04, 2021 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX , a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer ES-SCLC following two Phase 2 clinical trials. Results of the analyses, presented at the American Society of Clinical Oncology ASCO annual virtual meeting, demonstrated that patients receiving COSELA prior to chemotherapy had greater peripheral T-cell clonal expansion than patients receiving placebo. The goal of clonal expansion is to amplify the number of specific lymphocytes B-cells and T-cells to enable the body to have sufficient numbers of antigen-specific lymphocytes to mount an effective immune response. The eAbstract is available in the scientific publications section of G1s website. 